Aclarion, Inc., a commercial-stage healthcare technology company, announced it has received a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category. The award recognizes the company's use of augmented intelligence in its Nociscan solution for chronic low back pain, a condition affecting approximately 266 million people worldwide and representing one of healthcare's most pervasive and costly challenges.
This recognition follows Aclarion's earlier selection as a 2025 Digital Health Awards at HLTH winner, where Nociscan was honored for its potential to transform the evaluation and management of discogenic low back pain. Together, the Pinnacle and HLTH awards reflect growing external validation of Aclarion's mission to bring objective, MR spectroscopy-based biomarker analysis into routine clinical decision-making while advancing a new model of MedTech innovation built on scalable, cloud-based algorithms.
"Receiving recognition from both the Pinnacle Awards and HLTH underscores the accelerating momentum behind our technology. Chronic low back pain remains one of the most challenging and costly conditions in medicine. Providing physicians with objective biochemical data has the potential to fundamentally improve how discogenic pain is evaluated and treated," said Brent Ness, CEO of Aclarion.
Aclarion's flagship platform, Nociscan, uses MR spectroscopy to identify chemical biomarkers within intervertebral discs. These biomarkers are processed through proprietary algorithms that classify whether a disc's biochemical profile is consistent with a painful or non-painful disc. Physicians use this information—alongside imaging, clinical evaluation, and their own expertise—to optimize treatment planning for patients with discogenic low back pain. Clinical data demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools for evaluating chronic low back pain. Since Nociscan is delivered through a cloud-based analytics platform, it can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.
Chronic low back pain remains a global healthcare problem, and the company's technology aims to address the significant diagnostic gap. For more information about Aclarion and Nociscan, visit the company's website or view the latest news.
